Reports hinting that Michelle McMurry-Heath’s days as president and chief executive of the Biotechnology Innovation Organization (BIO) might be numbered have circulated in recent days.
On Monday, the trade group for the US biotech industry confirmed that Dr McMurry-Heath was stepping down from the top job, although she will remain an advisor to the executive committee of the BIO board of directors.
"The strategy of BIO remains on track"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze